High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy
Jiun‐Ruey Hu, Ameet Patel, Shi Huang, Yan Su, Kimberly B. Dahlman, Kelsey Tomasek, Yueli Zhang, Richard T. O’Neil, Jamye F. O’Neal, Isik Turker, Douglas B. Johnson, Joe‐Elie Salem, Javid J. Moslehi, Olalekan O. Oluwole
Abstract
= 0.002). Median NTproBNP was 179 pg/mL (IQR: 116, 325) at baseline, 357 pg/mL (IQR: 98, 813) at day 1, 420 pg/mL (IQR: 239, 1242) at day 7, and 177 pg/mL (IQR: 80, 278) at day 21. In conclusion, hsTropT l did not differ across timepoints after CAR T therapy, but NTproBNP rose at day 7, the prognostic implications of which should be the target of future research, as the indications for this therapy expand.
Topics & Concepts
Interquartile rangeMedicineTroponin TInternal medicineBiomarkerTroponinProspective cohort studyNatriuretic peptideGastroenterologyCardiologyMyocardial infarctionHeart failureChemistryBiochemistryCAR-T cell therapy researchIntegrated Circuits and Semiconductor Failure AnalysisAdvancements in Semiconductor Devices and Circuit Design